Journal
CELL
Volume 180, Issue 6, Pages 1098-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.02.042
Keywords
-
Categories
Funding
- Burroughs Wellcome CAMS
- Concern Foundation
- Slay Sarcoma Research Initiative
- Sarcoma Program at UPenn
- NIH [F30CA236464]
- [NCI-R37CA234027]
Ask authors/readers for more resources
The immunosuppressive tumor microenvironment (TME) is a major barrier to immunotherapy. Within solid tumors, why monocytes preferentially differentiate into immunosuppressive tumor-associated macrophages (TAMs) rather than immunostimulatory dendritic cells (DCs) remains unclear. Using multiple murine sarcoma models, we find that the TME induces tumor cells to produce retinoic acid (RA), which polarizes intratumoral monocyte differentiation toward TAMs and away from DCs via suppression of DC-promoting transcription factor Irf4. Genetic inhibition of RA production in tumor cells or pharmacologic inhibition of RA signaling within TME increases stimulat monocyte-derived cells, enhances T cell-dependent anti-tumor immunity, and synergizes with immune checkpoint blockade. Furthermore, an RA-responsive gene signature in human monocytes correlates with an immunosuppressive TME in multiple human tumors. RA has been considered as an anti-cancer agent, whereas our work demonstrates its tumorigenic capability via iediated immune suppression and provide proof of concept for targeting this pathway for tumor immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available